The Visible Hand: Government Supports the Biopharmaceutical Industry - The Indian government is providing several incentives for local biopharmaceutical companies to grow and compete globally. - BioPh

ADVERTISEMENT

The Visible Hand: Government Supports the Biopharmaceutical Industry
The Indian government is providing several incentives for local biopharmaceutical companies to grow and compete globally.


BioPharm International
Volume 21, Issue 8

FUTURE OUTLOOK

India's plans for promoting its biopharmaceutical and other biotech sectors are fairly ambitious and may be more difficult to realize as swiftly as the country's planners would like. As with many government initiatives around the globe, the DBT's budget (approaching $200 million in 2008) would seem to be spread thinly if it is to accommodate the long list of priority projects the organization intends to support.9

Still, India clearly is intent on improving itself in the biotech sector, and the desire to make Indian biotech as good as Indian IT seems to be widespread. It is, therefore, likely that in another decade, India will at least have one of Asia's best biotech capabilities.

REFRENCES

1. Biocon looks to Rs 650-cr SEZ for tax relief. The Hindu Business Line. 2005 Oct 20. Available from: http://www.thehindubusiness-line.com/2005/10/20/stories/2005102001630200.htm

2. The Patents Amendment Act, 2005. Available from: http://www.patentoffice.nic.in/ipr/patent/patent_2005.pdf

3. Yarnell A. Keeping postdocs at home in India. Chem Eng News 84. 2006 Mar 20. Available from: http://www.pubs.acs.org/cen/coverstory/84/8412India3.html

4. Department of Biotechnology. National Biotechnology Development Strategy. 2007 Nov. Available from: http://www.dbtindia.nic.in/biotechstrategy/National%20Biotechnology%20Development%20Strategy.pdf

5. Department of Plant and Molecular Biology, University of Delhi. India's national biotechnology regulatory authority functional in two years. Available from: http://www.south.du.ac.in/pmb/mod.php?mod=publisher&op=viewarticle&artid=55

6. Kumar A. Biogeneric manufacturing in India. In: Langer E, editor. Advances in biopharmaceutical technology in India. Gaithersburgh, MD: Bioplan; 2008 Feb.

7. Singh S. India doles out pharma incentives. Red Herring. 2007 Feb 27. Available from: http://www.redherring.com/Home/21468

8. India Brand Equity Foundation/Ernst & Young. Biotechnology. Available from: http://www.tamilnadunri.com/Indian%20Market/26.%20Bio-technology.pdf

9. Clearstate Pte. Ltd. Biotech: India's new global pitch. 2007 Jul 23. Available from: http://www.clearstate.com/admin/data/Clearstate_India_Biotech.pdf

Eric S. Langer is president and managing partner at BioPlan Associates, Inc., Rockville, MD. He is also the editor of Advances in Biopharmaceutical Technology in India, 301.921.9074,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Celgene and Sutro Partner on ADC Development
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Author Guidelines
Source: BioPharm International,
Click here